Immatics
Healthcare & Life Sci
Company overview
Immatics is a biotechnology company developing cancer immunotherapies that target the PRAME protein on tumor cells, which is expressed in more than 50 cancers. Anzu-cel, also called anzutresgene autoleucel or IMA203, is a T-cell therapy. IMA402 is a bispecific therapeutic.
Immatics is headquartered in Tubingen, Germany, with additional offices in Munich and Stafford, Texas. It is a public company.
- Industry
- Healthcare & Life Sci
- Headquarters
- 2 offices, United States